These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23733369)

  • 1. A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.
    Galvanin F; Ballan CC; Barolo M; Bezzo F
    J Pharmacokinet Pharmacodyn; 2013 Aug; 40(4):451-67. PubMed ID: 23733369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models.
    Siripuram VK; Wright DFB; Barclay ML; Duffull SB
    J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):415-423. PubMed ID: 28612141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural identifiability analysis of pharmacokinetic models using DAISY: semi-mechanistic gastric emptying models for 13C-octanoic acid.
    Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):279-92. PubMed ID: 21347679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review: To be or not to be an identifiable model. Is this a relevant question in animal science modelling?
    Muñoz-Tamayo R; Puillet L; Daniel JB; Sauvant D; Martin O; Taghipoor M; Blavy P
    Animal; 2018 Apr; 12(4):701-712. PubMed ID: 29096725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASAS-NANP symposium: Mathematical Modeling in Animal Nutrition: The power of identifiability analysis for dynamic modeling in animal science:a practitioner approach.
    Muñoz-Tamayo R; Tedeschi LO
    J Anim Sci; 2023 Jan; 101():. PubMed ID: 37997927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal experimental requirements for structural identifiability in linear compartmental models. The software 'IDEXMIN'.
    Mérino JA; de Biasi J; Plusquellec Y; Houin G
    Arzneimittelforschung; 1996 Mar; 46(3):324-8. PubMed ID: 8901159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What do we mean by identifiability in mixed effects models?
    Lavielle M; Aarons L
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):111-22. PubMed ID: 26660913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural identifiability of PBPK models: practical consequences for modeling strategies and study designs.
    Slob W; Janssen PH; van den Hof JM
    Crit Rev Toxicol; 1997 May; 27(3):261-72. PubMed ID: 9189655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.
    Hooker A; Vicini P
    AAPS J; 2005 Nov; 7(4):E759-85. PubMed ID: 16594631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parameter Identifiability of Fundamental Pharmacodynamic Models.
    Janzén DL; Bergenholm L; Jirstrand M; Parkinson J; Yates J; Evans ND; Chappell MJ
    Front Physiol; 2016; 7():590. PubMed ID: 27994553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
    Gibiansky L; Gibiansky E
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An iterative identification procedure for dynamic modeling of biochemical networks.
    Balsa-Canto E; Alonso AA; Banga JR
    BMC Syst Biol; 2010 Feb; 4():11. PubMed ID: 20163703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimally sufficient experimental design using identifiability analysis.
    Gevertz JL; Kareva I
    NPJ Syst Biol Appl; 2024 Jan; 10(1):2. PubMed ID: 38184643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DAISY: a new software tool to test global identifiability of biological and physiological systems.
    Bellu G; Saccomani MP; Audoly S; D'Angiò L
    Comput Methods Programs Biomed; 2007 Oct; 88(1):52-61. PubMed ID: 17707944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural identifiability and sensitivity.
    Iliadis A
    J Pharmacokinet Pharmacodyn; 2019 Apr; 46(2):127-135. PubMed ID: 30895420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local identifiability and sensitivity analysis of neuromuscular blockade and depth of hypnosis models.
    Silva MM; Lemos JM; Coito A; Costa BA; Wigren T; Mendonça T
    Comput Methods Programs Biomed; 2014; 113(1):23-36. PubMed ID: 24252467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical identifiability and convergence evaluation for nonlinear pharmacokinetic models with particle swarm optimization.
    Kim S; Li L
    Comput Methods Programs Biomed; 2014 Feb; 113(2):413-32. PubMed ID: 24216078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design and analysis of parallel experiments to produce structurally identifiable models.
    Cheung SY; Yates JW; Aarons L
    J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):93-100. PubMed ID: 23300030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing parameter identifiability in compartmental dynamic models using a computational approach: application to infectious disease transmission models.
    Roosa K; Chowell G
    Theor Biol Med Model; 2019 Jan; 16(1):1. PubMed ID: 30642334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.